Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacific Biosciences ( (PACB) ) has provided an update.
On March 2, 2026, Pacific Biosciences said Chief Accounting Officer Michele Farmer had resigned effective March 21, 2026, to pursue another opportunity, with the company emphasizing there was no disagreement over accounting or other practices and no severance to be paid. Chief Financial Officer Jim R. Gibson, who has held that role since 2025, will add the responsibilities of principal accounting officer without a change in compensation.
On March 5, 2026, the company entered a binding term sheet with Personal Genomics of Taiwan, Inc. that grants PacBio a worldwide, royalty-free, non-exclusive license to a key U.S. patent family and a five-and-a-half-year covenant not to sue, in exchange for fixed payments potentially totaling up to $23 million through 2029. The deal will end ongoing litigation between the parties, convert legal uncertainty into defined, time-bound protection, and is intended to support PacBio’s long-read sequencing growth strategy and provide greater operational certainty for its commercial ecosystem.
The most recent analyst rating on (PACB) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.
Spark’s Take on PACB Stock
According to Spark, TipRanks’ AI Analyst, PACB is a Neutral.
The score is held down primarily by weak financial fundamentals (large ongoing losses, cash burn, and a deteriorated balance sheet) and bearish technicals (below key moving averages with negative MACD). The latest earnings call provides partial support via margin/cost improvement progress and modest 2026 growth guidance, but valuation remains constrained by unprofitability and no dividend support.
To see Spark’s full report on PACB stock, click here.
More about Pacific Biosciences
Pacific Biosciences of California, Inc. is a life sciences company focused on advanced DNA sequencing technologies, particularly long-read sequencing platforms. Its products support a commercial ecosystem serving genomics researchers and clinical markets that depend on high-accuracy, long-read data for applications in human health, agriculture, and other scientific fields.
Average Trading Volume: 7,137,540
Technical Sentiment Signal: Strong Sell
Current Market Cap: $459M
See more data about PACB stock on TipRanks’ Stock Analysis page.